Inter-rater reliability of programmed death ligand 1 (PD-L1) scoring using the VENTANA PD-L1 (SP263) assay in Non-Small-Cell-Lung Cancer (NSCLC)
This year’s Nobel Prize in Physiology or Medicine for discoveries relating to the harnessing of the immune system in the treatment of cancer has highlighted the great benefits of this approach to therapy. Multiple immunotherapies targeting the immune checkpoint programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) pathway are now approved for the treatment of patients with various cancers, including non-small cell lung cancer (NSCLC) and urothelial carcinoma (UC).
However an ongoing clinical challenge is to identify those patients who are most likely to respond to such immunotherapies. Tests that can identify responders to such therapies are called companion diagnostics. Clinical data from multiple studies across several indications have demonstrated that PD-L1 expression level can be used to enrich for responders to PD-1/PD-L1 targeted monotherapy. The VENTANA PD-L1 (SP263) companion diagnostic assay represents one of the most widely used tests for predicting response anti-PD-L1 immune checkpoint inhibitors.
Oncologica in collaboration with AstraZeneca have recently completed a ring study in which we assessed the Inter-reader Reliability of Programmed Death Ligand-1 (PD-L1) Scoring using the VENTANA PD-L1 (SP263) Assay in Non-Small Cell Lung Cancer (NSCLC). This study was presented at this year’s ESMO 2018 congress taking place in Munich, Germany. Here we presented data showing that assessment of tumour cell (TC) scores by expert pathologists is highly reproducible in NSCLC tumour samples using the VENTANA PD-L1 (SP263) Assay, thus building confidence in the performance of this assay as a companion diagnostic for anti-PD-L1 therapy.